New NNRTI MK-1439 interacts with ritonavir but not tenofovir
Dolutegravir shows good efficacy across broad range of patient groups
New tenofovir formulation works equally well with less effect on kidneys and bones
CD4 gene therapy may enable functional HIV control during treatment interruption
Long-acting GSK1265744 and TMC278-LA appear safe and practical in early study
Dolutegravir superior to raltegravir for treatment-experienced people with HIV
Study supports WHO recommendations for second-line HIV therapy in resource-limited countries
Kick, kill, contain – researchers examine three possible steps in a cure for HIV
New recommendations on HIV treatment for children require earlier diagnosis, new drug combinations for maximum impact
